[Form 4] Royalty Pharma plc Insider Trading Activity

Rhea-AI Filing Summary

Royalty Pharma plc executive George W. Lloyd, EVP, Investments & CLO, reported multiple sales of Class A Ordinary Shares of RPRX on 11/19/2025. The transactions, coded as open-market sales, were executed under a Rule 10b5-1 trading plan adopted on August 20, 2025, meaning they followed a pre-set schedule. Shares were sold indirectly through several family-related entities, with weighted average prices generally between about $37.77 and $39.34 per share, and smaller sales from directly held shares.

After the reported sales, Lloyd continues to hold Class A Ordinary Shares through multiple vehicles, as well as limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 7,527,320 Class A Ordinary Shares. He also holds 1,944,471 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, some of which may convert into an equivalent number of Class A Ordinary Shares upon vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lloyd George W.

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Investments & CLO

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	11/19/2025		S(1)		47,798	D	$38.2788(2)	10,712	I	By GWL 2023 G HoldCo LLC
Class A Ordinary Shares	11/19/2025		S(1)		4,628	D	$39.0077(3)	6,084	I	By GWL 2023 G HoldCo LLC
Class A Ordinary Shares	11/19/2025		S(1)		47,401	D	$38.2787(2)	4,599	I	By GWL 2020 G, LLC
Class A Ordinary Shares	11/19/2025		S(1)		4,599	D	$39.0071(3)	0	I	By GWL 2020 G, LLC
Class A Ordinary Shares	11/19/2025		S(1)		25,530	D	$38.2789(2)	2,470	I	By GWL 2021 G, LLC
Class A Ordinary Shares	11/19/2025		S(1)		2,470	D	$39.0067(3)	0	I	By GWL 2021 G, LLC
Class A Ordinary Shares	11/19/2025		S(1)		2,770	D	$38.2858(4)	230	D
Class A Ordinary Shares	11/19/2025		S(1)		230	D	$39.0331(5)	0	D
Class A Ordinary Shares								495,860	I	By GWL 2013 NG, LLC
Class A Ordinary Shares								220,000	I	By GWL 2014 G, LLC
Class A Ordinary Shares								273,960	I	By IRA
Class A Ordinary Shares								4,011.19	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.79 to $38.78 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.79 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the holdings of Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 7,527,320 Class A Ordinary Shares. The Reporting Person also holds 1,944,471 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, certain of which are subject to vesting conditions and may, upon vesting, be converted into an equivalent number of Class A Ordinary Shares.

	/s/ Sean Weisberg, as Attorney-in-Fact for George W. Lloyd	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Royalty Pharma (RPRX) disclose in this Form 4 filing?

The filing reports that George W. Lloyd, EVP, Investments & CLO of Royalty Pharma plc, sold multiple blocks of Class A Ordinary Shares of RPRX on 11/19/2025, including both directly held and indirectly held shares through family-related entities.

Were the RPRX insider share sales made under a Rule 10b5-1 plan?

Yes. The filing states that all reported transactions were effected under a Rule 10b5-1 trading plan adopted by George W. Lloyd on August 20, 2025, indicating the sales followed a pre-arranged plan.

At what prices did George W. Lloyd sell Royalty Pharma Class A shares?

The filing discloses weighted average sale prices, with transactions executed in ranges such as $37.77 to $38.76, $38.77 to $39.34, and $37.79 to $38.78 per share. The weighted averages reported include values like $38.2788 and $39.0077 per share.

How many Royalty Pharma shares does George W. Lloyd still beneficially own after these sales?

After the reported sales, Lloyd holds various indirect positions including 495,860 Class A Ordinary Shares via GWL 2013 NG, LLC, 220,000 Class A Ordinary Shares via GWL 2014 G, LLC, 273,960 Class A Ordinary Shares via an IRA, and 4,011.19 Class A Ordinary Shares through his spouse, along with other previously listed vehicles.

What additional Royalty Pharma-related interests does George W. Lloyd hold?

The remarks state that Lloyd and family vehicles hold limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 7,527,320 Class A Ordinary Shares, and he also holds 1,944,471 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, some of which may vest and convert into Class A Ordinary Shares.

What is George W. Lloyd’s role at Royalty Pharma (RPRX)?

According to the filing, George W. Lloyd is an Officer of Royalty Pharma plc, serving as EVP, Investments & CLO and is a reporting person for these transactions.